Rabeprazole is effective for bile reflux oesophagitis after total gastrectomy in a rat model

AIM:To elucidate the effect of a proton pump inhibitor(PPI,rabeparazole)on oesophageal bile reflux in oesophagitis after total gastrectomy.METHODS:Twenty-one 8-week-old male Wistar rats were studied.They were performed oesophagoduodenostomy of total gastrectomy to induce oesophageal reflux of biliary and pancreatic juice.Five rats were performed the sham operation(Sham).On post-operative day 7,they were treated with saline(Control)(n=8)or PPI(rabeprazole,30 mg/kg per day,ip)(n=8)for 2 wk.On post-operative 21,all rats were sacrificed and each oesophagus was evaluated histologically.Oesophageal injury was evaluated by macroscopic and microscopic findings as well as the expression of cyclooxygenase-2(COX2).We measured bile acid in the oesophageal lumen and the common bile duct.RESULTS:At 3 wk after surgery,a histological study analysis revealed an increase in the thickness of the epithelium,elongation of the lamina propria and basal cell hyperplasia in the oesophageal mucosa.The macroscopic ulcer score and microscopic ulcer length of the control group were significantly higher compared to those of the rabeprazole-treated group.The expression of COX2 was significantly increased according to the immunostaining in the control group compared to rabeprazole-treated group.Although there was no difference between the control and PPI groups in the total bile acid in the common bile duct,the bileacid activity in the oesophageal lumen was significantly decreased in the rabeprazole-treated group due to augmentation of the duodenal motor complex.CONCLUSION:With this model,rabeprazole is good effect for reflux esophagitis after total gastrectomy from bile reflux.Bile acid is an important factor in the mucosal lesion induced by duodenal reflux.

Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study

AIM:To evaluate the efficacy of adding irsogladine maleate(IM) to proton-pump inhibitor(PPI) therapy in non-erosive reflux disease(NERD) treatment.METHODS:One hundred patients with NERD were recruited and randomized to receive rabeprazole plus IM(group I) or rabeprazole plus placebo(group P).The efficacy of the treatment was assessed using the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease(FSSG) and the short form(SF)-36 quality of life questionnaires after four weeks of treatment.We also assessed whether patients with NERD with minimal changes(grade M) had different responses to the therapies compared with patients who did not have minimal changes(grade N).RESULTS:Group I and group P showed significant improvements in their FSSG scores after the treatment(from 17.9 ± 7.9 to 9.0 ± 7.6, and from 17.7 ± 7.3 to 11.2 ± 7.9, respectively, P = 0.0001), but there was no statistically significant difference between the FSSG scores in group I and those in group P.Subgroup analysis showed that significant improvements in the FSSG scores occurred in the patients in group I who had NERD grade N(modified Los Angeles classification)(7.8 ± 7.4 vs 12.5 ± 9.8, P = 0.041).The SF-36 scores for patients with NERD grade N who had received IM and rabeprazole were significantly improved in relation to their vitality and mental health scores.CONCLUSION:The addition of IM to rabeprazole significantly improves gastroesophageal reflux diseasesymptoms and the quality of the lives of patients with NERD grade N.

A prospective randomized trial of lafutidine vs rabeprazole on post-ESD gastric ulcers

AIM:To compare the effects of rabeprazole and lafutidine on post-endoscopic submucosal dissection(ESD) gastric ulcers.METHODS:Patients with gastric tumors indicated for ESD were prospectively studied.After ESD,all patients were treated with intravenous omeprazole for the first 3 d.Patients were then randomly assigned to oral lafutidine or rabeprazole.Ulcer size,ulcer size reduction rate,and ulcer stage were evaluated 4 wk later.Occurrence of complication was monitored throughout the 4-wk period.RESULTS:Sixty five patients were enrolled in the study,and 60 patients were subjected to the final analysis.In the lafutidine group(30 lesions in 29 patients),initial and 4-wk post-ESD ulcer sizes were 33.3 ± 9.2 and 10.5 ± 4.8 mm,respectively.In the rabeprazole group(34 lesions in 31 patients),the values were 34.7 ± 11.3 and 11.8 ± 6.7 mm,respectively.Ulcer size reduction rates in lafutidine and rabeprazole groups were 32.3% and 33.5%,respectively(P=0.974).Ulcer stage 4 wk post-ESD did not differ significantly between the two groups(P=0.868).Two cases in the rabeprazole group and no cases in the lafutidine group developed ulcer bleeding during the oral dose period,although the difference of bleeding rate between the two groups was not statistically significant(P=0.157).CONCLUSION:Lafutidine and rabeprazole have equivalent therapeutic effects on post-ESD gastric ulcers.

CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication

AIM To evaluate the impact of cytochrome P450 2C19(CYP2C19) and interleukin-1β(IL-1β) polymorphisms on the efficacy of Helicobacter pylori(H. pylori) eradication by using rabeprazole-based hybrid therapy.METHODS A total of 88 H. pylori-infected patients were recruited to receive 14-d of hybrid therapy from March 2013 to May 2014. Three patients were excluded from analysis because of incomplete compliance. Either a follow-up endoscopy or 13 C-urea test was performed to determine the results of H. pylori eradication therapy. The genotypes of CYP2C19 and IL-1β were analyzed to investigate the impact on treatment effect. RESULTS The total eradication rate of H. pylori was 92.94%(79/85). According to the CYP2C19 genotypes, the rates of H. pylori eradication were 89.19% in extensive metabolizers(EM) and 95.83% in non-EM. The H.pylori eradication rates regarding the IL-1β genotypes were 92.59% in the normal acid secretion group and 93.10% in the low acid secretion group. After multivariable logistic regression analysis, both the genotypes of CYP2C19 and IL-1β had no significant influences on the eradication rates of H. pylori.CONCLUSION The CYP2C19 and IL-1β polymorphisms are not significantly independent factors of H.pylori eradication using rabeprazole-based hybrid therapy.

Development and validation of a high throughput UPLC–MS/MS method for simultaneous quantification of esomeprazole,rabeprazole and levosulpiride in human plasma

A high throughput ultra pressure liquid chromatography-mass spectrometry （UPLC-MS/MS） method with good sensitivity and selectivity has been developed and validated for simultaneous quantification of esomeprazole, rabeprazole and levosulpiride in human plasma using lansoprazole as internal standard （IS）. The extraction method based on liquid-liquid extraction technique was used to extract the analytes and IS from of 50 μL of human plasma using methyl tert-butyl ether：ethyl acetate （80：20, v/v）, which offers a high recovery. Chromatographic separation of analytes and IS was achieved on a Hypersil gold C18 column using gradient mobile phase consisting of 2 mM ammonium formate/acetonitrile. The flow rate was set at 0.5 mL/min to elute all the analytes and IS within 1.00 min runtime. Detection of target compounds was performed on a triple quadruple mass spectrometer by multiple reaction monitoring （MRM） mode via positive electrospray ionization （ESI）. Method validation results demonstrated that the developed method has good precision and accuracy over the concentration ranges of 0.1-2000 ng/mL for each analyte. Stability of compounds was established in a battery of stability studies, i.e., bench top, autosampler, dry extract and long-term storage stability as well as freeze-thaw cycles. The validated method has been successfully applied to analyze human plasma samples for application in pharmaco- kinetic studies.

Propagation of Airy beams from right-handed material to left-handed material

Based on the ABCD matrix formalism,the propagation property of an Airy beam from right-handed material（RHM） to left-handed material（LHM） is investigated.The result shows that when the Airy beam propagates in the LHM,the intensity self-bending due to its propagation in the RHM can be compensated.In particular,if the propagation distance in the RHM is equal to that in the LHM and the refractive index of the LHM is n L =-1,the transverse intensity distribution of the Airy beam can return to its original state.

Ten mg dexrabeprazole daily is as effective as 20 mg dexrabeprazole daily

Ten mg dexrabeprazole daily has been shown to be more effective than 20 mg rabeprazole daily against gastroesophageal reflux disease (GERD). This report shows that the efficacy of 10 mg dexrabeprazole daily is equivalent to that of 20 mg dexrabeprazole daily against GERD. This implies that a dose of 10 mg dexra- beprazole is sufficient to block the maximum amount of proton pumps without any need to double the dose as suggested with rabeprazole.

Stability-indicating HPLC-DAD methods for determination of two binary mixtures:Rabeprazole sodium-mosapride citrate and rabeprazole sodium-itopride hydrochloride

Two selective stability-indicating HPLC methods are described for determination of rabeprazole sodium （RZ）-mosapride citrate （MR） and RZ-itopride hydrochloride （IO） mixturcs in the presence of their ICH-stress formed degradation products. Separations were achieved on X-Bridge CI 8 column using two mobile phases： the first for RZ-MR mixture consisted of acetonitrile： 0.（125 M KH,PO4 solution： TEA （30：69：1 v/v; pH 7.0）; the second for RZ-IO mixture was at ratio of 25：74：1 Iv/v： pH 9.25J. The detection wavelength was 283 nm. The two methods were validated and wdidation acceptance criteria were met in all cases. Peak purity testing using contrast angle theory, relative absorbance and log A versus the wavelengths plots were presented. The % recoveries of the intact drugs were between 99.1% and 102.2% with RSD% values less than 1.6%. Application of the proposed HPLC methods indicated that the methods could be adopted to follow the stability of their formulations.

Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease

AIM：TO compare the efficacy and safety of dexrabe-prazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease （GERD）.METHODS： This was a randomized, double-blind clinical study. Fifty patients with GERD were randomly assigned to receive dexrabeprazole 10 mg or rabeprazole 20 mg once daily. Efficacy was assessed by evaluating improvement in visual analog scale （VAS） scores of heart-burn and regurgitation and safety was assessed by recording incidence of any adverse drug reactions. Laboratory investigations and upper gastro-intestinal endoscopy was conducted at baseline and after 28 d of therapy.RESULTS： A total of 50 patients （n = 25 in dexrabeprazole group and rabeprazole group each） completed the study. There were no significant differences in the baseline characteristics between the two groups. The VAS score （mean 4. SD） of heartburn and regurgitation in dexrabeprazole （64.8±5.1 and 64 ± 8.1, respectively） and rabeprazole （64.4 ± 8.7 and 57.6 ± 9.7, respectively） groups significantly reduced （P 〈 0.0001） to 30 ± 11.5, 24 ± 10 and 32 ± 9.5, 29.2±11.9, respectively on d 28. A significantly higher （P = 0.002） proportion of patients showed ≥ 50% improvement in regurgitation with dexrabeprazole 10 mg （96%） compared to rabeprazole 20 mg （60%）. Onset of symptom improvement was significantly earlier with dexrabeprazole than with rabeprazole （1.8 ± 0.8 d vs 2.6 ± 1.4 d; P 〈0.05）. The incidences of esophagitis in the dexrabeprazole group and rabeprazole group before therapy were 84% and 92%, respectively （P = 0.38）. The incidence of improvement/healing of esophagitis after therapy was more （P = 0,036） in the dexrabeprazole group （95.2%） compared to the rabeprazole group （65.2%）. No adverse drug reaction was seen in either group.CONCLUSION： In the treatment of GERD, efficacy of dexrabeprazole 10 mg is better than rabeprazole 20 mg, with regards to improvement/healing of endoscopic lesions and relief from symptoms of regurgitation.

Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan

AIM: To investigate the effi cacy and safety of rabepra-zole under continuous non-steroidal anti-inflammatory drug (NSAID) administration for NSAID-induced ulcer in Japan. METHODS: Subjects comprised patients undergoing NSAID treatment in whom upper gastrointestinal en-doscopy revealed an ulcerous lesion (open ulcer) with diameter ≥ 3 mm, who required continuous NSAID treatment. Endoscopies were performed at the start of treatment, during the treatment period, and at the conclusion (or discontinuation) of treatment. Findings were evaluated as size (maximum diameter) and stage based on the Sakita-Miwa classifi cation. An ulcer was regarded as cured when the "white coating" was seen to have disappeared under endoscopy. As criteria for evaluating safety, all medically untoward symptoms and signs (adverse events, laboratory abnormalities, accidental symptoms, etc.) occurring after the start of rabeprazole treatment were handled as adverse events.RESULTS: Endoscopic cure rate in 38 patients in the efficacy analysis (endoscopic evaluation) was 71.1% (27/38). Among those 38 patients, 35 had gastric ulcer with a cure rate of 71.4% (25/35), and 3 had duodenal ulcer with a cure rate of 66.7% (2/3). Three adverse drug reactions were reported from 64 patients in the safety analysis (interstitial pneumonia, low white blood cell count and pruritus); thus, the incidence rate for adverse drug reactions was 4.7% (3/64).CONCLUSION: The treatment efficacy of rabeprazole for NSAID-induced ulcer under continuous NSAID ad-ministration was confi rmed.

Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: Report of an efficacy study

AIM: To investigate the efficacy of a standard triple therapy (comprising rabeprazole, clarithromycin, and amoxicillin) for Helicobacter pylori (H. pylori) eradication, noting factors that influence the outcome and documenting any adverse events.

Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: Results of a study in a primary care setting

AIM： To determine the diagnostic value of the rabeprazole test in patients seen by general practitioners. METHODS： Eighty-three patients with symptoms suggestive of GERD were enrolled by general practitioners in this multi-centre, randomized and doubleblind study. All patients received either rabeprazole （20 mg bid） or a placebo for one week. The diagnosis of GERD was established on the presence of mucosal breaks at endoscopy and/or an abnormal esophageal 24-h pH test. The test was considered to be positive if patients reported at least a ＂clear improvement＂ of symptoms on a 7-point Likert scale. RESULTS： The sensitivities of the test for rabeprazole and the placebo were 83% and 40%, respectively. The corresponding specificity, positive and negative predictive values were 45% and 67%, 71% and 71%, and 62% and 35%, respectively. A receiver operating characteristics （ROC） analysis confirmed that the best discriminatory cut-off corresponded to description of ＂clear improvement＂ CONCLUSION： The poor specificity of the proton-pump inhibitor （PPI） test does not support such an approach to establish a diagnosis of GERD in a primary care setting.

A monolithic distributed phase shifter based on right-handed nonlinear transmission lines at 30 GHz

The epitaxial material, device structure, and corresponding equivalent large signal circuit model of GaAs planar Schottky varactor diode are successfully developed to design and fabricate a monolithic phase shifter, which is based on right-handed nonlinear transmission lines and consists of a coplanar waveguide transmission line and periodically distributed GaAs planar Schottky varactor diode. The distributed-Schottky transmission-line-type phase shifter at a bias voltage greater than 1.5 V presents a continuous 0°–360° differential phase shift over a frequency range from 0 to 33 GHz. It is demonstrated that the minimum insertion loss is about 0.5 dB and that the return loss is less than-10 dB over the frequency band of 0–33 GHz at a reverse bias voltage less than 4.5 V. These excellent characteristics, such as broad differential phase shift, low insertion loss, and return loss, indicate that the proposed phase shifter can entirely be integrated into a phased array radar circuit.

兰索拉唑与雷贝拉唑治疗食管癌术后反流性食管炎的疗效比较

目的比较兰索拉唑与雷贝拉唑对食管癌术后反流性食管炎患者的治疗效果。方法收集2019年8月—2023年10月绵阳市中心医院心胸外科诊治食管癌术后反流性食管炎患者202例,按照随机数字表法分为研究组101例和对照组101例。对照组术后常规支持治疗及雷贝拉唑钠肠溶胶囊口服,研究组常规支持治疗及兰索拉唑胶囊口服。比较2组患者术后、治疗4周后消化功能相关指标(Gas、MTL、CGRP)及血清炎性相关指标(IL-4、IL-6、IL-17、IL-23)水平变化及药物不良反应,并比较治疗4周后的临床疗效。结果治疗4周后2组总有效率比较差异无统计学意义(P>0.05);治疗4周后,研究组Gas及MTL均高于对照组,CGRP低于对照组(t/P=9.550/<0.001,7.735/<0.001,12.398/<0.001);血清IL-6、IL-17及IL-23水平均低于对照组,IL-4高于对照组(t/P=13.039/<0.001,22.533/<0.001,7.635/<0.001,7.682/<0.001)。2组患者治疗过程中总不良反应发生率比较差异无统计学意义(P>0.05)。结论兰索拉唑及雷贝拉唑均能显著缓解食管癌术后反流性食管炎患者的症状,其中兰索拉唑能更好地改善患者消化功能、降低炎性反应水平,具有更广阔的临床应用前景。

蒲元和胃胶囊联合雷贝拉唑治疗反流性食管炎的临床评价

目的 观察蒲元和胃胶囊联合雷贝拉唑治疗反流性食管炎的作用。方法 纳入河南大学第一附属医院胸外科2022年6月至2024年1月收治的102例反流性食管炎患者,以随机数字表法分成观察组(51例)与对照组(51例),给予对照组患者雷贝拉唑治疗,给予观察组患者蒲元和胃胶囊联合雷贝拉唑治疗,对比2组临床疗效、上腹痛、反酸与嗳气症状缓解时间、治疗前后反流性疾病问卷(RDQ)评分及胃动素、胃泌素水平以及不良反应情况。结果 观察组总有效率(96.08%)比对照组(84.31%)更高(χ^(2)=3.991,P<0.05);观察组患者的上腹痛、反酸与嗳气症状缓解时间分别为(6.15±0.52) d、(5.80±0.52) d、(5.52±0.38) d,均分别短于对照组患者(8.44±0.73) d、(7.38±0.66) d、(6.72±0.82) d,t=18.247、13.429、9.482,P<0.001;观察组患者治疗后症状发作频率评分为(3.99±0.52)分,症状发作程度评分为(5.48±0.69)分,均短于对照组治疗后评分(6.24±0.67)分、(7.42±0.72)分,t=18.946、13.893,P<0.001;观察组患者治疗后胃动素、胃泌素水平分别为(331.29±4.92) ng·L^(-1)、(178.54±4.37) pg·m L^(-1),均高于对照组(299.54±5.23) ng·L^(-1)、(143.25±4.92) pg·m L^(-1),t=31.577,P<0.001;观察组(3.92%)与对照组不良反应率(5.88%)差异无统计学意义,χ^(2)=0.210,P>0.05。结论 蒲元和胃胶囊结合雷贝拉唑治疗反流性食管炎效果良好,患者症状缓解快,胃肠功能恢复良好,治疗不良反应较少,值得应用。

加味柴胡桂枝干姜汤治疗伴睡眠障碍胃食管反流病的效果

目的观察加味柴胡桂枝干姜汤治疗伴睡眠障碍胃食管反流病的临床效果。方法选取2022年1月至2023年11月三明市第二医院70例伴睡眠障碍胃食管反流病患者作为研究对象,按照随机数字表法分为对照组和观察组,每组35例。对照组采用雷贝拉唑肠溶片,观察组在对照组基础上联合采用加味柴胡桂枝干姜汤。比较两组患者临床效果、中医证候总积分、胃食管反流病问卷量表(GerdQ)评分、匹茨堡睡眠质量指数(PSQI)评分、1周平均每天反酸次数及睡眠时间。结果观察组中医证候总积分、GerdQ评分、PSQI评分、1周平均每天反酸次数低于对照组,临床效果优于对照组,差异有统计学意义(P<0.05);观察组1周平均每晚睡眠时间长于对照组,差异有统计学意义(P<0.05)。结论加味柴胡桂枝干姜汤治疗伴睡眠障碍胃食管反流病患者比单用西药雷贝拉唑肠溶片效果更佳,能有效改善消化系统症状,提升睡眠质量,减少反酸次数,延长睡眠时间。

生长抑素联合雷贝拉唑治疗肝硬化上消化道出血的效果分析

目的:分析生长抑素联合雷贝拉唑治疗肝硬化上消化道出血的效果。方法:选取2020年8月—2022年10月滨州市中心医院收治的肝硬化上消化道出血患者76例作为研究对象,采用随机数字表法分为对照组与观察组,各38例。对照组给予雷贝拉唑治疗,观察组在对照组基础上予以生长抑素治疗。比较两组治疗效果。结果:观察组止血总有效率高于对照组,差异有统计学意义(P=0.042)。治疗后,两组血流动力学指标、凝血功能指标优于治疗前,且观察组优于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:生长抑素联合雷贝拉唑治疗肝硬化上消化道出血的效果显著,可增强止血效果,改善血流动力学及凝血功能,且安全性高。

荆花胃康胶丸联合雷贝拉唑四联疗法治疗Hp感染性消化性溃疡的效果及对溃疡愈合情况的影响

目的探讨荆花胃康胶丸联合雷贝拉唑四联疗法治疗幽门螺杆菌(Hp)感染性消化性溃疡的效果及对溃疡愈合情况的影响。方法选取2021年3月至2023年3月收治的76例Hp感染性消化性溃疡患者为研究对象,将其随机分为对照组与观察组,各38例。对照组采用雷贝拉唑四联疗法,观察组在对照组基础上加荆花胃康胶丸治疗。比较两组的治疗效果。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗后,观察组的肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)及降钙素原(PCT)水平均低于对照组(P<0.05)。治疗后,观察组的溃疡愈合情况优于对照组(P<0.05)。治疗后,观察组的世界卫生组织生存质量测定量表简表(WHOQOL-BREF)各维度评分均高于对照组(P<0.05)。结论荆花胃康胶丸联合雷贝拉唑四联疗法治疗Hp感染性消化性溃疡的效果显著,不仅能抑制炎性浸润,还能促进溃疡愈合,改善患者生活质量。

慢性萎缩性胃炎规范化治疗效果分析

目的:分析消化内科临床规范化治疗应用于慢性萎缩性胃炎的效果。方法:选取吉林省四平市中心人民医院于2023年1月至12月期间收治的80例慢性萎缩性胃炎患者为研究对象,对照组采用常规治疗,观察组采用规范化治疗,根据病情选用替普瑞酮联合雷贝拉唑钠开展药物治疗,对比两组患者在治疗期间的各项指标。结果:治疗后,患者的临床指标均得到有效改善,其中观察组患者治疗有效率、幽门螺杆菌清除率以及转阴、复发率均优于对照组患者,数据差异明显(P<0.05)。结论:使用替普瑞酮联合雷贝拉唑钠进行规范化药物治疗,能够有效改善患者体内幽门螺杆菌数量,提高整体治疗有效率。